Association of opioid agonist therapy with lower incidence of hepatitis C virus infection in young adult injection drug users
about
Opioids and Viral Infections: A Double-Edged SwordAgent-Based Model Forecasts Aging of the Population of People Who Inject Drugs in Metropolitan Chicago and Changing Prevalence of Hepatitis C InfectionsPublic health and international drug policy.Barriers to Hepatitis C Virus (HCV) Treatment Initiation in Patients With Human Immunodeficiency Virus/HCV Coinfection: Lessons From the Interferon Era.Prevalence of hepatitis C virus infection among HIV+ men who have sex with men: a systematic review and meta-analysis.Incidence and prevalence of hepatitis c virus infection among persons who inject drugs in New York City: 2006-2013.Biomedical HIV Prevention Including Pre-exposure Prophylaxis and Opiate Agonist Therapy for Women Who Inject Drugs: State of Research and Future Directions.Insufficient access to harm reduction measures in prisons in 5 countries (PRIDE Europe): a shared European public health concernA longitudinal study of hepatitis C virus testing and infection status notification on behaviour change in people who inject drugsTrends and risk factors for HIV, HCV and syphilis seroconversion among drug users in a methadone maintenance treatment programme in China: a 7-year retrospective cohort studyThe role of living context in prescription opioid injection and the associated risk of hepatitis C infection.Buprenorphine Initiation and Linkage to Outpatient Buprenorphine do not Reduce Frequency of Injection Opiate Use Following Hospitalization.Direct-acting antiviral agents for HCV infection affecting people who inject drugs.Utilization of buprenorphine and methadone among opioid users who inject drugs.Research priorities to achieve universal access to hepatitis C prevention, management and direct-acting antiviral treatment among people who inject drugs.Scaling up HCV prevention and treatment interventions in rural USA - model projections for tackling an increasing epidemic.HCV Cure and Reinfection Among People With HIV/HCV Coinfection and People Who Inject Drugs.Buprenorphine implants in medical treatment of opioid addiction.Ongoing incident hepatitis C virus infection among people with a history of injecting drug use in an Australian prison setting, 2005-2014: The HITS-p study.Update on pharmacotherapy for treatment of opioid use disorder.Needle syringe programmes and opioid substitution therapy for preventing HCV transmission among people who inject drugs: findings from a Cochrane Review and meta-analysis.Elimination of HCV as a public health concern among people who inject drugs by 2030 - What will it take to get there?HCV reinfection incidence among individuals treated for recent infection.Hepatitis C elimination by 2030 through treatment and prevention: think global, act in local networks.Recommendations for the management of hepatitis C virus infection among people who inject drugs.Commentary on Zhou et al. (2015): Research on methadone maintenance treatment (MMT) as prevention for HCV infection--MMT is not a single variable.The effect of female sex on hepatitis C incidence among people who inject drugs: results from the international multi-cohort InC3 Collaborative.Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs.Addressing opioid use disorder in modeling hepatitis C transmission among persons who inject drugs.Continued Transmission of HIV Among Young Adults Who Inject Drugs in San Francisco: Still Room for Improvement.Only One In Twenty Justice-Referred Adults In Specialty Treatment For Opioid Use Receive Methadone Or Buprenorphine.Evaluation of Methadone Treatment in Malaysia: Findings from the Malaysian Methadone Treatment Outcome Study (MyTOS).Importance and Contribution of Community, Social, and Healthcare Risk Factors for Hepatitis C Infection in Pakistan.Knowledge of hepatitis C status moderates the relationship between history of drug treatment and sterile syringe use.A Public Health Analysis on Gaps in Disease Monitoring and Opportunities for Improved Care for the Management of Hepatitis B and C.Suboxone: Rationale, Science, Misconceptions.Geographic Differences in Temporal Incidence Trends of Hepatitis C Virus Infection Among People Who Inject Drugs: The InC3 CollaborationImpact of current and scaled-up levels of hepatitis C prevention and treatment interventions for people who inject drugs in three UK settings-what is required to achieve the WHO's HCV elimination targets?Buprenorphine-based opioid substitution therapy in India: A few observations, thoughts, and opinions
P2860
Q26742182-6B2633AC-511D-46BF-A6D5-2A4607DE1A86Q28548643-10971D71-CDA4-4514-A038-9DE1E189E400Q30377895-8D382DE9-3AFB-428A-A452-F36639E405D1Q33629538-820C0B74-63B1-40BB-AC4C-6CFB87AD6443Q34511438-39B4D1CB-F1C3-4E00-9525-4DC57A2C0E1DQ35690302-0960933A-3A39-41F9-946D-74C718FAFA0CQ35817533-04C9CB2B-6925-42B4-A8FD-F29B2A979D1AQ35823557-4AB47A09-78A1-46A4-B196-E044494FBC7DQ35889562-CB5CAE8D-6603-4859-BEC9-23C7FDC731ACQ35999052-9ADB9A49-A8B8-4091-86BC-E60806BBC32BQ36033587-9C8F75A0-6DB1-4E13-A08E-DC1C06755632Q36080932-65FEDA6E-96E7-4616-827C-9F849E7128F1Q38613271-CBF9571C-629C-4DB8-BCB9-C847FBB22D3DQ38630550-6BBF5541-96E8-4463-ACEB-BE357CF7BF66Q38661825-CF1DCAD0-BC5D-467F-9848-98A99BED383AQ38666907-018207DC-6FBE-4EEA-92B2-D97683D0AFF8Q38692113-04747D7C-A7F9-493B-8B12-6900EC3F9C72Q38750450-64156A34-7C7E-4F81-A7E6-2053259BDCCCQ38931620-B046A44B-2D2D-4EA4-8DCC-5E90D50EBFC6Q38979423-235EF98E-2218-4AD1-9268-74C6A2A81C59Q40048259-B5900F24-C76B-46FA-8A42-60217233CCE2Q40092669-FEEA9B95-CCCA-44E7-8ABC-0C9191781AB0Q40393982-DA2726E3-0C13-4239-9051-ECB95516D3F3Q40637053-A61124B1-0429-401B-87B9-05BFF7BB9266Q41047662-FFDEA5AA-AC70-4A8F-80B3-3525B7D773EEQ41338757-D1A484EF-8CA5-4076-844B-F8DF4E05C663Q41919161-79757F32-DF52-4BAE-9927-563D280A6A8EQ42720607-4DE606D6-64D6-41BE-800A-21C3D94825CFQ44342795-6DC047F1-EFA6-4126-A8A9-B4D74CAF48C8Q46964805-DC68CD0C-F6C1-47B5-A580-A647E09E2DD4Q47376071-CEDE06CF-C4B9-4EA9-B277-61387FCA72BBQ47578057-0B67B306-9434-49B3-B185-CB8099A386AAQ47579352-69D490B5-0FF5-49E2-A0EE-BB240D1D4EA7Q52558293-4963F36E-51C9-4E62-ADF5-36B1367D3056Q52645814-8EFD84E0-83B1-4D9F-84F8-850391804F87Q52645984-2DE0B522-854E-49FD-ACE4-FFD3381A1BBEQ56556912-CB0AFA9D-96B0-4AA1-A941-CED8113A2BF2Q57700826-8A49EFC5-BB2D-4505-9237-A0BEBC71A299Q58569574-11543F77-DD84-4B33-9F25-FF7AF766C739
P2860
Association of opioid agonist therapy with lower incidence of hepatitis C virus infection in young adult injection drug users
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Association of opioid agonist ...... ung adult injection drug users
@ast
Association of opioid agonist ...... ung adult injection drug users
@en
type
label
Association of opioid agonist ...... ung adult injection drug users
@ast
Association of opioid agonist ...... ung adult injection drug users
@en
prefLabel
Association of opioid agonist ...... ung adult injection drug users
@ast
Association of opioid agonist ...... ung adult injection drug users
@en
P2093
P2860
P1476
Association of opioid agonist ...... ung adult injection drug users
@en
P2093
Jennifer L Evans
Judith A Hahn
Judith I Tsui
Paula J Lum
P2860
P304
P356
10.1001/JAMAINTERNMED.2014.5416
P577
2014-12-01T00:00:00Z